Tenax Therapeutics Inc
tenaxthera.comWhat Do They Do?
Develops oral levosimendan for people with pulmonary hypertension associated with heart failure, alongside imatinib for pulmonary arterial hypertension.
10-K for FY2025, filed Mar 10, 2026Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary…View ↗
In the fourth quarter of 2023, we initiated the LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients), an ongoing…View ↗
TNX-201 (imatinib) has the potential to be the first disease-modifying treatment of PAH, a fatal orphan disease. Pulmonary vasodilators…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Jul 31, 2026
−$17.8MView ↗
- ▲ +64% (Loss)
- vs −$10.8M in Q2 FY2025
-
Apr 22, 2026
Tenax appointed a new chief financial officer
Thomas R. Staab, II was appointed effective May 11, 2026, replacing interim CFO Thomas McGauley.
Sources
8-K, filed Apr 22, 2026
On April 22, 2026, Tenax Therapeutics, Inc. (the “Company”) announced the appointment of Thomas R. Staab, II as Chief Financial Officer of…View ↗
Who Do They Compete With?
Competes with Astra Zeneca, Tectonic, Merck, and GSK
10-K for FY2025, filed Mar 10, 2026We believe the concept of using TNX-101/102/103 (levosimendan) to treat patients with PH-HFpEF is novel, and the patent granted for this…View ↗
Loading...
